Fedratinib in patients with myelofibrosis previously treated with ruxolitinib: An updated analysis of the JAKARTA2 study using stringent criteria for ruxolitinib failure

Fedratinib is an oral, selective Janus kinase 2 (JAK2) inhibitor. The phase II JAKARTA2 study assessed fedratinib in patients with intermediate‐ or high‐risk myelofibrosis (MF) who were resistant or intolerant to prior ruxolitinib per investigator assessment. Patients received fedratinib 400 mg/day...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Yayımlandı:Am J Hematol
Asıl Yazarlar: Harrison, Claire N., Schaap, Nicolaas, Vannucchi, Alessandro M., Kiladjian, Jean‐Jacques, Jourdan, Eric, Silver, Richard T., Schouten, Harry C., Passamonti, Francesco, Zweegman, Sonja, Talpaz, Moshe, Verstovsek, Srdan, Rose, Shelonitda, Shen, Juan, Berry, Tymara, Brownstein, Carrie, Mesa, Ruben A.
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: John Wiley & Sons, Inc. 2020
Konular:
Research Articles
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC7317815/
https://ncbi.nlm.nih.gov/pubmed/32129512
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/ajh.25777
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller